GW announces UK launch of world’s first prescription cannabis medicine

GW Pharmaceuticals plc today announces the UK launch of Sativex®, its Oromucosal Spray for the treatment of spasticity due to Multiple Sclerosis (MS). Sativex® is the world’s first prescription cannabis medicine and the UK is the first country in the world to grant a full regulatory authorization for the product.

Sativex®, available as a prescription only medicine, was developed by GW in specific response to calls from people with MS for a prescription cannabis-based medicine. Today's launch means that MS patients suffering the spasms and cramping associated with spasticity have access to a new treatment option which has been shown to improve their symptoms where current treatments have failed.

For more information go to their website here

Written evidence for the House of Lords

Science and Technology Select Committee

This article is still on our old site - click here to read full article

Click here to download as pdf

Sub-Committee I: Cannabis.

Submission of the Independent Drug Monitoring Unit (I.D.M.U.)